A BIOTECH company has been launched to research and develop new gene therapies to target various forms of cancer.
Cellinta LTD – which was formed through an investment by SV Health Investors and Cancer Research UK – will be used to build a pipeline of highly selective gene therapies targeting cancer stem cells in various types of solid tumours.
The company draws on research conducted at the University of Edinburgh led by professor Steven Pollard across stem cell biology, synthetic biology and cancer genomics.
READ MORE: Boeing partners with Scots group for massive research project
Pollard is professor of stem cell and cancer biology at the university’s Centre for Regenerative Medicine and Edinburgh Cancer Research UK Centre and is the scientific founder and senior adviser to the new company.
He said: “It’s an extremely exciting time in the gene therapy field. With Cellinta, we can ensure that our discoveries and technologies can now be rapidly developed into new therapeutics that can be used to treat aggressive cancers with high unmet need.”
Cellinta LTD will be led by CEO Dr Soraya Bekkali, who has more than 20 years experience in drug development and business strategy, with a focus on gene therapy.
“I am delighted to be leading such an exciting company,” said Bekkali. “Cellinta’s approach offers the opportunity to deliver combinations of therapies selectively to cancer stem cells, bypassing the limitations of traditional treatments which often target single genes or redundant signalling pathways.”
READ MORE: Wait for licensing system for Airbnb-style lets in Scotland
Bekkali said gene therapy can potentially overcome some of the drug delivery challenges encountered by past drug candidates.
The company has entered a collaborative research agreement with the university and has an option to license intellectual property developed at the university.
Mike Ross, managing partner at SV Health Investors, has been appointed chairman of Cellinta.
He said: “Cellinta represents a unique opportunity to build a leading company based on exciting and innovative science, with the potential to develop first-in-class therapies.
“We are delighted with the progress the company has made and extremely pleased to appoint Soraya, who has deep experience in gene therapy across various therapeutic areas, as CEO.”
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereLast Updated:
Report this comment Cancel